医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Otsuka Chemical Succeeded Part of the Cefixime Business from Astellas Pharma

2019年06月05日 PM03:00
このエントリーをはてなブックマークに追加


 

TOKYO

Otsuka Chemical Co., Ltd. (Head office: Chuo-Ku, Osaka; President & Representative Director: Takeharu Harashima; hereinafter “Otsuka Chemical”) announces that it has succeeded part of the Cefixime business from Astellas Pharma, Inc. (Head Office: Chuo-Ku, Tokyo; President & CEO: Kenji Yasukawa, Ph.D.; hereinafter “Astellas Pharma”).

Through this agreement, Otsuka Chemical acquires the business of Cefixime from Astellas Pharma to supply the API (Active Pharmaceutical Ingredient) to overseas licensees along with assets such as contracts belonging to the licensing business and the trademark. This means our company’s entry into the API business, resulting in strengthening the integrated antibiotic-related business from intermediates to API.

Cefixime developed by Astellas Pharma is a third-generation cephalosporin with antibacterial activity against gram-positive and gram-negative bacteria and it is extensively prescribed worldwide.

In addition to the main business field of chemicals, Otsuka Chemical will continue strengthening the manufacturing technology of high-quality API and their marketing and brand power to promote pharmaceutical-related business and CMO business by taking advantage of key technologies cultivated in the field of organic and inorganic chemicals.

 

Company Profile

 

Otsuka Chemical Co., Ltd.
Established   :   August 29, 1950
Capital : 5 billion yen
President : Takeharu Harashima, President and Representative Director
Head Office : 3-2-27, Ote-Dori, Chuo-Ku, Osaka, 540-0021 Japan
Employees : 1,857 (consolidated; as of December 31, 2018)
Business Description

:

 

Manufacturing and sales of chemical products

 

Astellas Pharma Inc.

Established   :   April 1923
Capital : 103 billion yen
President : Kenji Yasukawa, President and CEO
Head Office : 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, Japan
Employees : 16,243 (consolidated; as of March 31, 2019)

Business Description

:

  Research and development, manufacturing, and sales of pharmaceuticals
 

View source version on businesswire.com: https://www.businesswire.com/news/home/20190604006187/en/

CONTACT

Hidetosihi Hironishi
Otsuka Chemical Co., Ltd.
General Affairs
Occ.Release@otsuka.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Celltrion Healthcare showcases positive 1-year data and budget impact analysis for novel subcutaneous formulation of infliximab in patients with rheumatoid arthritis at the European E-Congress of Rheumatology 2020
  • Exosite授权West Pharmaceutical Services, Inc.使用其物联网技术
  • 武田将呈报ICLUSIG® (ponatinib)临床试验项目数据,这些数据有望改变慢性期CML治疗的实践
  • 武田薬品、高リスクMDS患者でpevonedistatとアザシチジンの併用療法を検討する第2相試験の有力なデータを発表
  • 武田发布Pevonedistat联合阿扎胞苷治疗较高危MDS患者2期试验的有力数据